TNYA insider Form 4 shows tax-related sale and 93,971 shares held

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. (TNYA) reported an insider transaction by its SVP, Finance. On 11/17/2025, the officer sold 1,367 shares of common stock at a price of $1.33 per share, coded as a sale to satisfy obligations. The filing explains that the shares were sold to cover tax withholding related to the vesting of restricted stock units granted on August 15, 2024.

After this transaction, the reporting person beneficially owns 93,971 shares of Tenaya Therapeutics common stock. This total includes 50,470 shares that will be issued upon the vesting of restricted stock units in the future.

Insider Trade Summary

Net Seller: 1,367 shares ($1,818)

Net Sell 1 txn

Insider Higa Tomohiro

Role SVP, Finance

Sold 1,367 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,367	$1.33	$2K

Holdings After Transaction: Common Stock — 93,971 shares (Direct)

Footnotes (1)

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024. Includes 50,470 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higa Tomohiro

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		1,367	D	$1.33	93,971(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on August 15, 2024.

2. Includes 50,470 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tenaya Therapeutics (TNYA) report in this Form 4?

The SVP, Finance of Tenaya Therapeutics (TNYA) reported selling 1,367 shares of common stock on 11/17/2025 at a price of $1.33 per share.

Why were shares of Tenaya Therapeutics (TNYA) sold in this filing?

The filing states that the 1,367 shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units granted on August 15, 2024.

How many Tenaya Therapeutics (TNYA) shares does the insider own after the transaction?

Following the reported sale, the SVP, Finance beneficially owns 93,971 shares of Tenaya Therapeutics common stock.

How many restricted stock unit (RSU) shares are included in the insider’s holdings at Tenaya Therapeutics (TNYA)?

The total beneficial ownership of 93,971 shares includes 50,470 shares of Tenaya Therapeutics common stock that will be issued upon the vesting of restricted stock units.

What is the relationship of the reporting person to Tenaya Therapeutics (TNYA)?

The reporting person is an officer of Tenaya Therapeutics, serving as SVP, Finance.

Is this Tenaya Therapeutics (TNYA) Form 4 filed for one or multiple reporting persons?

This Form 4 is indicated as filed by one reporting person, reflecting the holdings and transactions of the SVP, Finance only.